Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Jinyu Bio-technology Co., Ltd. (600201.SS)
CNY12.21
+0.30 (+2.52%)
CN SHH Healthcare Biotechnology
Address
No. 1, Jinyu Street 10030
Hohhot, CN
Hohhot, CN
CEO
Jing Zhang
Website
jinyu.com.cn
IPO
1999-01-15
ISIN CNE000000Y37
Description
Based in Hohhot, China, Jinyu Bio-technology Co., Ltd. is a Chinese firm specializing in the development, production, and commercialization of biological products for animal health. Established in 1992, the company provides crucial vaccines designed to combat diseases such as foot-and-mouth disease, highly pathogenic avian influenza, brucellosis, rabies, and swine fever. These vital immunizations are supplied for a broad spectrum of animals, including pigs, poultry, ruminants, and companion pets. The entity formally adopted its current name, Jinyu Bio-technology Co., Ltd., in December 2015, having previously operated as Inner Mongolia Jinyu Group Co., Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY12.21
+0.30 (+2.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
26M
Beta
0.65
Float Shares
923.98M
Free Float %
83.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -3.63% | -9.25% | -20.01% | -27.20% | -4.50% | -22.56% | +60.97% | +13.08% | -42.20% | -19.29% | +856.56% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
12.21
DCF (Unlevered)
4.32
-64.6%
DCF (Levered)
3.60
-70.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 5 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
9.28
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
4 / 5
High
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+11.2% ★ Q1'26: -1.5% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-6.2% Q1'26: +7.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+12.1% ★ Q1'26: -6.9% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+7.5% ★ Q1'26: +27.9% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+2.3% ★ Q1'26: +7.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-2.2% ★ Q1'26: -2.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.25B
est: 1.30B (-4.4%)
|
1.52B
est: 1.49B (+2.0%)
|
1.90B
est: 2.01B (-5.4%)
|
1.90B
est: 2.17B (-12.6%)
|
1.13B
est: 1.15B (-2.0%)
|
1.58B
est: 1.49B (+6.3%)
|
1.78B
est: 2.01B (-11.5%)
|
1.53B
est: 1.68B (-9.2%)
|
1.60B
est: 1.53B (+4.8%)
|
1.26B
est: 1.42B (-11.6%)
|
1.40B
est: 1.37B (+1.7%)
|
1.66B
1.65B – 1.67B
+20.7% YoY
|
1.75B
1.73B – 1.77B
+5.6% YoY
|
1.20B
1.19B – 1.21B
-31.3% YoY
|
| EBITDA |
642.35M
est: 381.04M (+68.6%)
|
801.73M
est: 434.61M (+84.5%)
|
1.03B
est: 587.44M (+75.1%)
|
896.82M
est: 634.55M (+41.3%)
|
318.77M
est: 336.18M (-5.2%)
|
580.63M
est: 434.99M (+33.5%)
|
585.17M
est: 586.84M (-0.3%)
|
450.92M
est: 491.91M (-8.3%)
|
437.17M
est: 413.33M (+5.8%)
|
246.61M
est: 385.08M (-36.0%)
|
363.89M
est: 372.07M (-2.2%)
|
449.03M
446.41M – 451.65M
+20.7% YoY
|
473.96M
468.61M – 479.32M
+5.6% YoY
|
325.44M
323.54M – 327.34M
-31.3% YoY
|
| EBIT |
570.87M
est: 216.22M (+164.0%)
|
742.83M
est: 246.62M (+201.2%)
|
966.36M
est: 333.35M (+189.9%)
|
800.02M
est: 360.07M (+122.2%)
|
211.68M
est: 190.77M (+11.0%)
|
406.99M
est: 246.84M (+64.9%)
|
394.19M
est: 333.00M (+18.4%)
|
252.01M
est: 279.14M (-9.7%)
|
248.70M
est: 197.45M (+26.0%)
|
37.19M
est: 183.95M (-79.8%)
|
105.09M
est: 177.74M (-40.9%)
|
214.50M
213.25M – 215.75M
+20.7% YoY
|
226.41M
223.85M – 228.97M
+5.6% YoY
|
155.46M
154.56M – 156.37M
-31.3% YoY
|
| Net Income |
479.73M
est: 558.84M (-14.2%)
|
644.54M
est: 598.78M (+7.6%)
|
870.09M
est: 832.33M (+4.5%)
|
754.47M
est: 879.31M (-14.2%)
|
221.04M
est: 279.69M (-21.0%)
|
406.20M
est: 411.08M (-1.2%)
|
382.29M
est: 602.80M (-36.6%)
|
210.66M
est: 286.78M (-26.5%)
|
283.63M
est: 268.54M (+5.6%)
|
108.99M
est: 225.78M (-51.7%)
|
100.11M
est: 145.14M (-31.0%)
|
306.41M
304.09M – 308.74M
+111.1% YoY
|
395.50M
299.22M – 517.88M
+29.1% YoY
|
731.09M
725.55M – 736.64M
+84.9% YoY
|
| SGA |
355.57M
est: 381.54M (-6.8%)
|
408.96M
est: 435.18M (-6.0%)
|
440.51M
est: 588.22M (-25.1%)
|
403.64M
est: 635.38M (-36.5%)
|
331.19M
est: 336.62M (-1.6%)
|
400.14M
est: 435.56M (-8.1%)
|
501.90M
est: 587.61M (-14.6%)
|
421.77M
est: 492.56M (-14.4%)
|
491.55M
est: 449.70M (+9.3%)
|
432.34M
est: 418.96M (+3.2%)
|
368.37M
est: 404.81M (-9.0%)
|
488.54M
485.69M – 491.40M
+20.7% YoY
|
515.67M
509.84M – 521.50M
+5.6% YoY
|
354.08M
352.01M – 356.15M
-31.3% YoY
|
| EPS |
0.47
est: 0.51 (-8.1%)
|
0.62
est: 0.54 (+13.8%)
|
0.77
est: 0.76 (+1.7%)
|
0.67
est: 0.80 (-16.3%)
|
0.20
est: 0.25 (-21.4%)
|
0.36
est: 0.37 (-2.9%)
|
0.34
est: 0.55 (-38.0%)
|
0.19
est: 0.26 (-27.2%)
|
0.26
est: 0.25 (+4.1%)
|
0.10
est: 0.21 (-52.4%)
|
0.09
est: 0.14 (-33.3%)
|
0.29
0.28 – 0.29
+111.1% YoY
|
0.38
0.28 – 0.48
+33.3% YoY
|
0.68
0.67 – 0.69
+78.9% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-25 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 3/5 | 3/5 | 4/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-08 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 2/5 | 3/5 | 4/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
368.07M
OE per share TTM
0.34
Owner's Yield
2.74%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
123.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 25 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Value ETF DFEV | 0.01% | 107.2K | 0.46% |
| 2 | Invesco FTSE All-World UCITS ETF FWRA.SW | 0.00% | 178.8K | 0.15% |
| 3 | Invesco FTSE All-World UCITS ETF FTWG.L | 0.00% | 178.5K | 0.15% |
| 4 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 247.5K | 0.39% |
| 5 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 91.0K | 0.17% |
| 6 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 91.0K | 0.17% |
| 7 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 191.0K | 0.06% |
| 8 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 31.8K | 0.26% |
| 9 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 14.1K | 0.48% |
| 10 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 96.0K | 0.29% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
63.5K
Shares Outstanding
1.11B
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Min Peng | Chief Financial Officer, Secretary of the Board of Directors & Director | 748.0K | male |
| Jing Zhang | Vice Chairman & President | 421.0K | female |
| Li Wen Wang | Accounting Supervisor | — | — |
| Rong Li | Vice President | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600201.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
